Edwards Lifesciences (EW)

• Market cap: $44.6B
• 1 day: -1.26%
• 5 days: -6.35%
• 1 month: -4.1%
• 3 months: 0.36%
• 6 months: 6.31%
• Year to date: 3.44%
• 1 year: 8.26%
• 5 years: -10.47%
• 10 years: 220.49%
• Sector: Healthcare
• Industry: Medical Devices

About: Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.

Employees: 15,800

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

80% more first-time investments, than exits

New positions opened: 164 | Existing positions closed: 91

70% more call options, than puts

Call options by funds: $254M | Put options by funds: $149M

9% more capital invested

Capital invested by funds: $36.1B [Q1] → $39.2B (+$3.1B) [Q2]

4% more funds holding

Funds holding: 1,186 [Q1] → 1,239 (+53) [Q2]

0.5% more ownership

Funds ownership: 85.03% [Q1] → 85.52% (+0.5%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 10 [Q1] → 10 (+0) [Q2]

6% less repeat investments, than reductions

Existing positions increased: 419 | Existing positions reduced: 448

Research analyst outlook

13 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $79
• Avg. target: $87
• High target: $95

13 analyst ratings

• positive: 7 54%
• neutral: 6 46%
• negative: 0 0%

Wells Fargo Larry Biegelsen	$88	Overweight Maintained	7 Aug 2025
JP Morgan Robbie Marcus	$85	Neutral Maintained	25 Jul 2025
Canaccord Genuity William Plovanic	$81	Hold Maintained	25 Jul 2025
Mizuho Anthony Petrone	$95	Outperform Maintained	25 Jul 2025
Truist Securities Richard Newitter	$82	Hold Maintained	25 Jul 2025